Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GMED - GenoMed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: jmhollen who wrote (135)	6/18/2004 2:19:45 PM
From: Tadsamillionaire	Respond to of 347

GenoMed's Novel Treatment Working for Post-West Nile Virus Encephalitis Syndrome Friday June 18, 9:35 am ET ST. LOUIS, June 18 /PRNewswire-FirstCall/ -- GenoMed, Inc. (Pink Sheets: GMED - News), a Next Generation DM(TM) (Disease Management) company that uses its expertise in genomics to improve clinical outcomes, announced today that its unique, patent-pending approach to West Nile virus encephalitis appears to work even months after the acute episode. Some people with West Nile virus encephalitis fail to recover completely even long after the acute episode. They may have headache, continued paralysis, weakness, fatigue, or tremors. Such residual symptoms are called post-West Nile virus encephalitis syndrome. West Nile virus is not the only virus which can cause them. Polio can do the same thing. GenoMed has now seen gratifying responses in two patients with post-WNV encephalitis syndrome. One patient had constant headaches for seven months after her episode of WNV encephalitis last summer. Her headaches disappeared within a week of starting GenoMed's experimental approach. A second patient, Mr. Thomas Cook, began GenoMed's treatment two months after West Nile virus encephalitis, when he was still paralyzed in his right leg. His story appeared yesterday on WCVB Channel 5, Boston at: thebostonchannel.com GenoMed's goal is to eliminate the threat of West Nile virus from the general population on the 50th anniversary of the famous 1954 polio field trials which ended the threat of polio in the U.S. For more information, click on the "West Nile trial" link at genomedics.com . About GenoMed GenoMed is leading the clinical revolution which medical genomics has already made possible. GenoMed is currently marketing its protocol for preventing kidney failure due to high blood pressure and diabetes, and delaying emphysema. Next summer it will begin charging a modest license fee for the use of its West Nile virus treatment protocol. Safe Harbor Statement This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether our treatment for West Nile virus encephalitis will remain effective for larger numbers of patients; (b) whether our server holds up to heavy demand; (c) our research and development being subject to other economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement. biz.yahoo.com

To: jmhollen who wrote (135)	6/22/2004 10:15:40 PM
From: Tadsamillionaire	Respond to of 347

Another summertime outbreak could focus investor attention on the companies working to combat this disease -- and on their other promising products. By Michael Brush It’s summertime, and the livin’ is easy. Unfortunately, so are you -- an easy target for mosquitoes and the West Nile virus they can carry. As tragic and frightening as this virus is for hundreds of victims and their families each year, there are a couple of reassuring things to keep in mind about this dreaded disease, which can kill victims by making their brains swell. As much as mosquitoes munch on us all summer, the chances are slim that any of us will actually get the virus. In a country of 290 million people, there were 9,862 confirmed cases and 264 deaths last year, primarily in Colorado, Nebraska, Texas and South Dakota. Several companies are working on promising vaccines and cures, as well as better ways to screen the public blood supply for the virus. First, the bad news We'll look at those companies in a moment with an eye to investing. But first, some bad news. West Nile may hit much harder this year, as it appears to be spreading to new states, including California, says Ray Parsons of MosquitoZone.com. Already, the state has reported 10 cases in 2004, and we aren’t even in the peak mosquito season of July and August. California reported just three cases through all of last year, according to the Centers for Disease Control.Check out your options. Find the best rate before you borrow. The disease may be much more widespread than the numbers suggest. Some experts think for every confirmed case of West Nile, which first showed up in the United States in a dead bird in the Bronx Zoo in 1999, there are several hundred unreported cases. Many people have West Nile virus and don’t know it, since the symptoms mimic those of the flu. Next, there’s a chance this may be the year that the mosquito-borne virus starts to spread down through Mexico and Central America and through Europe. (One possible case was reported in France last year, so it looks like it is already on that continent.) moneycentral.msn.com